Posted On: 10/25/2014 3:54:32 PM
Post# of 30066
Let your mind wonder on this one from Zacks...
Pharmacyclics (PCYC-Free Report) was in the news last week with the company signing an agreement with Roche under which its cancer treatment, Imbruvica, will be evaluated in combination with Roche’s Gazyva (Read more
harmacyclics, Roche Ink Deal for Cancer Combo Therapy). Moreover, Imbruvica gained EU approval for two types of blood cancer and Pharmacyclics is now looking to get Imbruvica’s label expanded in the U.S. for Waldenstrom's macroglobulinemia, a slow-growing, currently incurable, rare type of B-cell lymphoma
Now if we can come up with theory where AMBS gets a partnership with Roche because of our relationship with Pharmacyclics then Risk and JP can spin it into a "promise"?
Pharmacyclics (PCYC-Free Report) was in the news last week with the company signing an agreement with Roche under which its cancer treatment, Imbruvica, will be evaluated in combination with Roche’s Gazyva (Read more
harmacyclics, Roche Ink Deal for Cancer Combo Therapy). Moreover, Imbruvica gained EU approval for two types of blood cancer and Pharmacyclics is now looking to get Imbruvica’s label expanded in the U.S. for Waldenstrom's macroglobulinemia, a slow-growing, currently incurable, rare type of B-cell lymphoma Now if we can come up with theory where AMBS gets a partnership with Roche because of our relationship with Pharmacyclics then Risk and JP can spin it into a "promise"?
(0)
(0)
